REFERENCES
- Magee LA, Helewa M, Moutquin JM, von Dadelszen P. Diagnosis, evaluation and management of hypertensive disorders of pregnancy. J Obstet Gynaecol Can 2008; 30:S5.
- Menzies J, Magee LA, Li J, Instituting surveillance guidelines and adverse outcomes in preeclampsia. Obstet Gynecol 2007; 110:121–127.
- Altman D, Carroli G, Duley L, Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: A randomised placebo-controlled trial. Lancet 2002; 359:1877–1890.
- Drago JR, Nesbitt JA II, Leb R. Renal angiomyolipomas. J Surg Oncol 1988; 39:64–67.
- Fassler CA, Rodriguez RM, Badesch DB, Stone WJ, Marini JJ. Magnesium toxicity as a cause of hypotension and hypoventilation. Occurrence in patients with normal renal function. Arch Intern Med 1985; 145:1604–1606.
- Zwanger ML. Hypermagnesemia and perforated viscus. Ann Emerg Med 1986; 15:1219–1220.
- Spital A, Greenwell R. Severe hyperkalemia during magnesium sulfate therapy in two pregnant drug abusers. South Med J 1991; 84:919–921.
- Sipes SL, Weiner CP, Gellhaus TM, Goodspeed JD. The plasma renin-angiotensin system in preeclampsia: Effects of magnesium sulfate. Obstet Gynecol 1989; 73:934–937.
- Fuentes A, Goldkrand JW. Angiotensin-converting enzyme activity in hypertensive subjects after magnesium sulfate therapy. Am J Obstet Gynecol 1987; 156:1375–1379.